Skip NavigationSkip to Content

Phenotypic and Molecular Epidemiology of ESBL-, AmpC-, and Carbapenemase-Producing Escherichia coli in Northern and Eastern Europe

  1. Author:
    Sepp, Epp
    Andreson, Reidar
    Balode, Arta
    Bilozor, Anastasia
    Brauer, Age
    Egorova, Svetlana
    Huik,Kristi
    Ivanova, Marina
    Kaftyreva, Lidia
    Kõljalg, Siiri
    Kõressaar, Triinu
    Makarova, Maria
    Miciuleviciene, Jolanta
    Pai, Kristiine
    Remm, Maido
    Rööp, Tiiu
    Naaber, Paul
  2. Author Address

    Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Department of Bioinformatics, Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia., Department of Biology and Microbiology, Riga Stradinš University, Riga, Latvia., Department of Microbiology, Central Laboratory, East-Tallinn Central Hospital, Tallinn, Estonia., Department of Enteric Infections, St. Petersburg Pasteur Institute, Saint Petersburg, Russia., HIV Dynamics and Replication Program, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Department of Microbiology, Vilnius City Clinical Hospital, Vilnius, Lithuania., SYNLAB Eesti, Tallinn, Estonia.,
    1. Year: 2019
    2. Date: Nov 22
    3. Epub Date: 2019 11 22
  1. Journal: Frontiers in microbiology
    1. 10
    2. Pages: 2465
  2. Type of Article: Article
  3. Article Number: 2465
  4. ISSN: 1664-302X
  1. Abstract:

    Extended-spectrum beta-lactamases (ESBL) and AmpC producing-Escherichia coli have spread worldwide, but data about ESBL-producing-E. coli in the Northern and Eastern regions of Europe is scant. The aim of this study has been to describe the phenotypical and molecular epidemiology of different ESBL/AmpC/Carbapenemases genes in E. coli strains isolated from the Baltic States (Estonia, Latvia, and Lithuania), Norway and St. Petersburg (Russia), and to determine the predominant multilocus sequence type and single nucleotide polymorphisms diversity of E. coli isolates deduced by whole genome sequencing (WGS). A total of 10,780 clinical E. coli strains were screened for reduced sensitivity to third-generation cephalosporins. They were collected from 21 hospitals located in Estonia, Latvia, Lithuania, Norway and St. Petersburg during a 5 month period in 2012. The overall prevalence of ESBL/AmpC strains was 4.7% by phenotypical test and 3.9% by sequencing. We found more strains with the ESBL/AmpC phenotype and genotype in St. Petersburg and Latvia than other countries. Of phenotypic E. coli strains, 85% contained confirmed ESBL genes (including blaCTX-M, blaTEM-29, blaTEM-71), AmpC genes (blaCMY-59, blaACT-12/-15/-20, blaESC-6, blaFEC-1, blaDHA-1), or carbapenemase genes (blaNDM-1). blaCTX-M-1, blaCTX-M-14 and blaCTX-M-15 were found in all countries, but blaCTX-M-15 prevalence was higher in Latvia than in St. Petersburg (Russia), Estonia, Norway and Lithuania. The dominating AmpC genes were blaCMY-59 in the Baltic States and Norway, and blaDHA-1 in St. Petersburg. E. coli strains belonged to 83 different sequence types, of which the most prevalent was ST131 (40%). In conclusion, we generally found low ESBL/AmpC/Carbapenemase prevalence in E. coli strains isolated in Northern/Eastern Europe. However, several inter-country differences in distribution of particular genes and multilocus sequence types were found. Copyright © 2019 Sepp, Andreson, Balode, Bilozor, Brauer, Egorova, Huik, Ivanova, Kaftyreva, Kõljalg, Kõressaar, Makarova, Miciuleviciene, Pai, Remm, Rööp and Naaber.

    See More

External Sources

  1. DOI: 10.3389/fmicb.2019.02465
  2. PMID: 31824436
  3. PMCID: PMC6882919
  4. WOS: 000505252600001

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel